Biocare Medical announces the launch of RISH™ – A new chromogenic ISH technology: reducing protocol length from two days to approximately 2.5 hours.
In a simplified protocol the company has removed the need for RNase free solutions and labware, the overnight hybridization, and harsh stringent wash conditions. The proprietary DNA probe technology ensures high specificity and accuracy for the target.
The result: virtually no background, a clean chromogenic signal. Users can visualize the target under brightfield microscopy, along with the tissue morphology on a single slide. This 5-step procedure is as simple as IHC – helpint to bring what was once considered a tedious technology to every lab.
We will be launching with a small subset of probes initially, these RISH™ Probes are designed for the diagnosis and classification of hematopoietic and lymphoid neoplasms: EBER, Kappa, and Lambda Light Chain.
Source: Biocare Medical